Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...

CAR T-cell therapy is a personalized treatment that uses a patient’s own immune cells to fight cancer, making it effective but unsuitable for mass production, which increases the cost. The complex ...

A new, highly sensitive cell therapy was able to wipe out three different kinds of solid tumors in mice, an important advance in an area where CAR-T cells have long struggled. But significant ...

Avantor AVTR recently entered into a strategic partnership with BlueWhale Bio to accelerate innovation in CAR-T cell therapy manufacturing. The collaboration merges Avantor’s bioprocessing expertise ...

Avantor Inc. (NYSE:AVTR) is one of the best large cap stocks to buy under $20. On October 15, Avantor announced a partnership with BlueWhale Bio, which is a commercial-stage company that transforms ...

Proof-of-concept manufacturing to be provided by Cellares for a key Lyell CAR T-cell therapy using Cellares' exclusive Cell Shuttle Collaboration to evaluate potential utilization of the Cell Shuttle ...

This review article highlights the transformative potential of in vivo CAR T cell therapy in addressing the limitations of traditional CAR T cell production. This innovative approach could ...

ATALANTA-1 data presented at ASH 2025 showed remarkable response rates and rapid manufacturing with an investigational autologous CAR T-cell therapy. In this interview, Michael Wang, MD, comments on ...

Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked significant ...

Cause-Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study Healthy volunteers were recruited and underwent ...

Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...